EOLS at a glance
Evolus, Inc. (EOLS, SEC CIK 1570562) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Evolus, Inc. (EOLS) reported revenue of $297.2 million (up 11.6% from FY2024) and a net loss of $51.6 million. Diluted EPS was -$0.80.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Evolus, Inc. (EOLS) shares worth $104.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by MOATAZEDI DAVID on September 2, 2026 of 105,108 shares at $9.04 per share.
- In the last 90 days, EOLS insiders reported 0 open-market purchases ($0) and 1 open-market sale ($950K) on Form 4, a net sale of $950K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $297.2M
- +11.6% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$950K
- 13F holders
- 23 funds
- $104.4M · +1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- High investment risk from uncertainties described throughout the Form 10-Q
AI summary of the EOLS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue $84.1M, up 21%, with toxin revenue $75.2M and HA gel revenue $8.9M
- Adjusted EBITDA $4.7M versus $(7.9)M, marking the third consecutive positive quarter and $12.6M improvement
Item 1.01: Entry into a Material Definitive Agreement
- Exclusive Estyme injectable gel rights added in Canada, Australia and New Zealand
- €920,000 upfront payment plus up to €1.38 million tied to regulatory approvals
Item 7.01: Regulation FD Disclosure
- Evolus announced execution of an Amendment on August 4, 2026
- Press release furnished as Exhibit 99.1 contains the substantive Amendment details
Item EX-99.1: Item EX-99.1
- Exclusive Estyme rights expanded to Canada, Australia, and New Zealand, completing Evolus’ injectable portfolio coverage across existing commercial markets
- Addressable neurotoxin and dermal filler market approximately $500 million annually, with 60% neurotoxins and 40% dermal fillers
Item 7.01: Regulation FD Disclosure
- Evolus announced execution of an Agreement on July 8, 2026
- Exhibit 99.1 contains the related press release and substantive deal details
Item 1.01: Entry into a Material Definitive Agreement
- Exclusive U.S. license for Profhilo® aesthetics and dermatology applications, expanding Evolus beyond its existing product portfolio
- Evolus funds U.S. development, clinical trials and FDA approval, creating regulatory and commercialization costs
Item EX-99.1: Item EX-99.1
- Exclusive U.S. license with IBSA adds Profhilo, expanding Evolus beyond neurotoxins and fillers into skin-quality injectables
- Profhilo has generated over 4.8 million treatments across more than 70 countries since its 2015 launch
AI summaries of EOLS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for EOLS
Don't miss the next EOLS filing
- Alerts as it files. A push when EOLS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut EOLS, by share count.
- Ask anything. An AI agent that reads every EOLS filing and answers with sources.
EOLS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MOATAZEDI DAVID | Sell | Sep 2, 2026 | 105,108 | $9.04 |
| MOATAZEDI DAVID | Sell | Mar 20, 2026 | 13,669 | $4.75 |
| Avelar Rui | Sell | Mar 20, 2026 | 3,119 | $4.75 |
| Avelar Rui | Sell | Mar 17, 2026 | 29,996 | $4.89 |
| MOATAZEDI DAVID | Sell | Mar 17, 2026 | 116,720 | $4.89 |
| Avelar Rui | M | Mar 16, 2026 | 8,804 | - |
| Avelar Rui | M | Mar 16, 2026 | 8,804 | - |
| MOATAZEDI DAVID | M | Mar 16, 2026 | 67,489 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $266.3M | $297.2M |
| Gross Profit | - | $182.3M | $197.1M |
| Operating Income | - | -$34.4M | -$32.7M |
| Net Income | - | -$50.4M | -$51.6M |
| Gross Margin | - | 68.5% | 66.3% |
| Op. Margin | - | -12.9% | -11.0% |
| Net Margin | - | -18.9% | -17.4% |
| Balance Sheet | |||
| Total Assets | - | $232.6M | $225.9M |
| Equity | -$20.7M | $5.5M | -$23.1M |
| ROE | - | -913.1% | 223.5% |
| Per Share | |||
| EPS | - | $-0.81 | $-0.80 |
| Cash Flow | |||
| Operating CF | - | -$18.0M | -$42.3M |
| CapEx | $473K | $1.5M | $3.4M |
Source: XBRL data in Evolus, Inc. (EOLS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate EOLS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $104.4M |
| Q1 2026 | 22 | $57.6M |
| Q4 2025 | 24 | $117.1M |
| Q3 2025 | 23 | $103.4M |
| Q2 2025 | 23 | $145.4M |
| Q1 2025 | 22 | $139.9M |
| Q4 2024 | 17 | $101.6M |
| Q3 2024 | 16 | $89.7M |
- BlackRock+550.4K (+13%)
- State Street Corp+376.5K (+29%)
- Millennium Management+326.8K (+22%)
- Goldman Sachs Group+133.0K (+12%)
- AQR Capital Management+71.9K (+280%)
- D.E. Shaw & Co−222.1K (-40%)
- Citadel Advisors LLC−190.3K (-27%)
- Vanguard Capital Management LLC−107.5K (-4%)
- Bank of America Corp−82.0K (-53%)
- Renaissance Technologies LLC−36.5K (-11%)
- U.S. Bancorp+171
Source: 13F-HR filings on SEC EDGAR (aggregated from 170 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
EOLS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 4, 2026 | - | - | - |
| SC 13G | Aug 31, 2026 | - | - | |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | Mar 20, 2026 | - | - | - |
| 4 | Mar 20, 2026 | - | - | - |
| 4 | Mar 18, 2026 | - | - | - |
| 4 | Mar 18, 2026 | - | - | - |
| 8-K | Mar 13, 2026 | - | Analysis | - |
| 10-K | Mar 3, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - | |
| 4 | Feb 19, 2026 | - | - | |
| 8-K | Jan 9, 2026 | - | - | |
| 4 | Dec 29, 2025 | - | - | |
| 4 | Dec 29, 2025 | - | - | |
| 10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
| SC 13G | Aug 18, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
EOLS SEC filings: frequently asked questions
Are EOLS insiders buying or selling?
In the last 90 days, Evolus, Inc. (EOLS) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $950,019 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold EOLS stock?
As of June 30, 2026, the largest Evolus, Inc. (EOLS) holders among the 13F filers tracked by SignalX were BlackRock ($33.6 million), Vanguard Capital Management LLC ($16.4 million), Millennium Management ($12.4 million), State Street Corp ($11.8 million), Goldman Sachs Group ($8.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was EOLS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Evolus, Inc. (EOLS) reported revenue of $297.2 million (up 11.6% from FY2024) and a net loss of $51.6 million. Diluted EPS was -$0.80. The figures come from the XBRL data in the 10-K.
What did EOLS report in its latest 8-K?
Evolus, Inc. (EOLS) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest EOLS SEC filings?
Evolus, Inc. (EOLS) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 4, 2026.
What is EOLS's SEC CIK number?
Evolus, Inc. (EOLS)'s SEC Central Index Key (CIK) is 1570562. EDGAR lists every EOLS filing under that number.
Ask anything about EOLS
The research agent reads EOLS's filings, financials, insider trades and 13F holders, then answers with sources.